ABSI Absci Corp stock chart & analysis
Conviction 19HealthcareScan · Fri, Nov 6, 2026Absci Corp (ABSI) closed at $10.17 (+8.31%) on Nov 6, 2026. Price is above its 50-day and above its 200-day moving average. RSI(14) 51, RS Rating 99, -18.9% from its 52-week high, +191.4% year to date. Sector: Healthcare · Services-Commercial Physical & Biological Research.
Financials as of Tue, Jun 30, 2026 · quarterly.
ABSI technical analysis
Trend
ABSI is in an uptrend: price is above the 50-day, which is above the 200-day moving average. It closed 6.3% above the 50-day ($9.57) and 52.6% above the 200-day ($6.66). ADX(14) at 16 points to a weak trend — more range than direction. It meets 8 of 8 trend-template criteria.
Momentum
RSI(14) is 51, in the bullish half of its range. MACD crossed below its signal line one session ago. Its RS Rating of 99 puts its weighted 12-month performance ahead of about 99% of the US market.
Volume and volatility
Volume on the latest session ran 0.8× its 20-day average. It trades about $37.8M a day on average. ATR(14) is $1.01, 10.0% of price — its typical daily range. On-balance volume is trending up. Chaikin Money Flow (0.08) shows accumulation.
Key levels
The chart pattern's support is $8.47 and its resistance $12.22. The 52-week range is $2.24 to $12.54; price is 18.9% below the high and 354.0% above the low. The VWAP anchored at the 52-week high is $10.53, above price.
Performance
ABSI returned -8.6% (1 week), +13.8% (1 month), +12.9% (3 months), +72.4% (6 months), +166.9% (1 year), +191.4% (year to date).
About Absci Corp
Absci Corp is the Artificial intelligence powered synthetic biology company unlocking the potential of proteins as the next generation of therapeutics. It enables the creation of novel biologics by unifying biologic drug discovery and cell line development into one simultaneous process. Its lead product candidate, ABS-201, is an anti-prolactin receptor (PRLR) antibody engineered with an extended half-life to support a patient-friendly dosing interval.
Services-Commercial Physical & Biological Research · Listed 2021 · 140 employees
Insider activity
SEC Form 4 transactions in ABSI · open-market 1 buy
| Insider | Side | Shares | Value | Traded | Filed |
|---|---|---|---|---|---|
McClain Sean Chief Executive Officer · Common Stock · 2026-10-29 | Tax | 79.86K | $966K | 2026-10-29 | 2026-10-30 |
Jonasson Zachariah CFO / CBO · Common Stock · 2026-08-31 | Tax | 8.32K | $72K | 2026-08-31 | 2026-09-01 |
Somaratne Ransi Mudalinayake CMO, Head of R&D · Stock Option (right to buy) · 2026-08-03 | Grant | 383K | — | 2026-08-03 | 2026-08-07 |
Somaratne Ransi Mudalinayake CMO, Head of R&D · Stock Option (right to buy) · 2026-03-03 | Grant | 650K | — | 2026-03-03 | 2026-08-07 |
Szela Mary T Director · Common Stock · 2026-06-30 | Buy | 12.9K | $149K | 2026-06-30 | 2026-07-06 |
McClain Sean Chief Executive Officer · Common Stock · 2026-06-24 | Tax | 59.9K | $603K | 2026-06-24 | 2026-06-26 |
Rabinovitsj Daniel A Director · Stock Option (right to buy) · 2026-06-04 | Grant | 39.8K | $0 | 2026-06-04 | 2026-06-08 |
Szela Mary T Director · Common Stock · 2026-06-04 | Grant | 10.1K | $0 | 2026-06-04 | 2026-06-08 |
Szela Mary T Director · Stock Option (right to buy) · 2026-06-04 | Grant | 39.8K | $0 | 2026-06-04 | 2026-06-08 |
Rabinovitsj Daniel A Director · Common Stock · 2026-06-04 | Grant | 10.1K | $0 | 2026-06-04 | 2026-06-08 |
SEC filings
EDGAR filings in ABSI · 7 recent
Get daily signals & real-time alerts.
StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 7 days, no credit card.
Start free — 7-day trial, no card →Free daily signals by email. Top 3 setups per lane after every close. No account needed.
Unsubscribe anytime · Privacy
Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.